Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer

Gynecologic Oncology

Volumn 102, Issue 1, 2006, Pages 54-60

  Ho, Chih Ming ^a,b,c,d   Chien, Tsai Yen ^a   Huang, Shih Hung ^a   Lee, Bor Heng ^e   Chang, Shwu Fen ^d  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e King Car Food Industrial Co Ltd   (Taiwan)

Author keywords

Cervical intraepithelial neoplasia; HPV; Integration; Polymerase chain reaction; Viral load

Indexed keywords

VIRUS DNA;

ARTICLE; CANCER INVASION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SPECIES COMPARISON; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; NEOPLASM STAGING; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; VIRUS INTEGRATION;

EID: 33744934223     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.035     Document Type: Article

References (32)

1. Syrjanen K., and Syjanen S. Papillomavirus infection in human pathology (2000), J. Wiley and Sons, Inc., New York, NY 142-166
2. Zur Hausen H. Papillomavirus causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92 (2000) 690-698
3. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87 (1995) 796-802
4. Von Knebel Doeberitz M., Rittmuller C., Aengeneyndt F., Jansen-Durr P., and Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J. Virol. 68 (1994) 2811-2821
5. Choo K.B., Pan C.C., and Han S.H. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 161 (1987) 259-261
6. Jeon S.B., Allen-Hoffmann L., and Lambert P.F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69 (1995) 2989-2997
7. Boshart M., Gissman L., Ikenberg H., Kleinheinz A., Scheurlen W., and zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 3 (1984) 1151-1157
8. Vernon S.D., Unger E.R., Miller D.L., Lee D.R., and Reeves W.C. Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. Int. J. Cancer 74 (1997) 50-56
9. Peitsaro P., Johansson B., and Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J. Clin. Microbiol. 40 3 (2002) 886-891
10. Nagao S., Yoshinouchi M., Miyagi Y., Hongo A., Kodama J., Itoh S., et al. Rapid and sensitive detection of physical status of human papillomavirus type 16 DNA by quantitative real-time PCR. J. Clin. Microbiol. 40 3 (2002) 863-867
11. Badaracco G., Venuti A., Sedati A., and Marcante M.L. HPV 16 and HPV 18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness. J. Med. Virol. 67 (2002) 574-582
12. Das B.C., Sharma J.K., Gopalarishna V., and Luthra U.K. Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions. J. Gen. Virol. 73 (1992) 2327-2336
13. Joseffson A.M., Magnusson P.K.E., Ylitalo N., Sorensen P., Owarforth-Tubbin P., Andersen P.K., et al. Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355 (2000) 2189-2193
14. Liaw K.L., Hsing A.W., Chen C.J., Schiffman M.H., Zhang T.Y., Hsieh C.Y., et al. Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int. J. Cancer 62 (1995) 565-571
15. Huang S., Afonina I., Miller B.A., and Bechmann M. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese Women. Int. J. Cancer 70 (1997) 408-411
16. Ho C.M., Yang S.S., Chien T.Y., Huang S.H., Jeng C.J., and Chang S.F. Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. Gynecol. Oncol. 99 3 (2005) 615-621
17. Huang J., Huang S.L., Lin C.Y., Lin R.W., Chao F.Y., Chen M.Y., et al. Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int. J. Gynecol. Cancer 14 4 (2004) 639-649
18. Pirami L., Giache V., and Becciolini A. Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. J. Clin. Pathol. 50 7 (1997) 600-604
19. Sasagawa T., Basha W., Yamazaki H., and Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol. Biomark. Prev. 10 (2001) 45-52
20. Park J.S., Hwang E.S., Lee C.J., Kim C.J., Rha J.G., Kim S.J., et al. Mutational and functional analysis of HPV-16 URR derived from Korean cervical neoplasia. Gynecol. Oncol. 74 (1999) 23-29
21. Dong X.P., Stubenrauch F., Beyer-Finkler E., and Pfister H. Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers. Int. J. Cancer 58 6 (1994) 803-808
22. Alazawi W., Pett M., Strauss S., Moseley R., Gray J., Stanley M., et al. Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV 16 E2 gene and clinical outcome. Br. J. Cancer 91 (2004) 2063-2070
23. Dyson N., Howley P.M., Munger K., and Harlow E. The human papillomavirus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (Washington DC) 243 (1989) 934-937
24. Bremer G.L., Tieboschb A.T., van der Putten H.W., de Haan J., and Arends J.W. P53 tumor suppressor gene protein expression in cervical cancer: relationship to prognosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 63 1 (1995) 55-59
25. Moberg M., Gustavsson I., and Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int. J. Cancer 112 (2004) 854-859
26. Moberg M., Gustavsson I., Wilander E., and Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br. J. Cancer 92 (2005) 891-894
27. Lorincz A.T., Castle P.E., Sherman M.E., Scott D.R., Glass A.G., Wacholder S., et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 360 (2002) 228-229
28. Gravitt P.E., Burk R.D., Lorincz A., Herrero R., Hildesheim A., Sherman M.E., et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 477-484
29. Dalstein V., Riethmuller D., Pretet J.L., Carval K.L.B., Sautinere J.L., and Carbillet J.P. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int. J. Cancer 106 (2003) 396-403
30. Beskow A.H., Moberg M., and Gyllensten U.B. HLA class II allele control of HPV load in carcinoma in situ of the cervix uteri. Int. J. Cancer 117 3 (2005) 510-514
31. Sherman M.E., Schiffman M., and Cox J.T. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS). J. Natl. Cancer Inst. (Bethesda) 94 (2002) 102-107
32. Lefevre J., Hankins C., Money D., Rachlis A., Pourreaux K., et al., The Canadian Women's HIV Study Group. Human papillomavirus type 16 viral load is higher in human immunodeficiency virus-seropositive women with high-grade squamous intraepithelial lesions than in those with normal cytology smears. J. Clin. Microbiol. 42 5 (2004) 2212-2215